Gene-editing therapy by Vertex and CRISPR poised for FDA approval - The Boston Globe
bostonglobe.comSubmitted by thebostonglobe7305 in health
The life-changing drug, developed by Boston-based Vertex and its Swiss partner CRISPR Therapeutics, targets sickle cell disease, an inherited blood disorder that causes crippling pain.